# **Appendix 3B**

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

ivame	ΟI	entity	

Metminco Limited ABN

43 119 759 349

We (the entity) give ASX the following information.

#### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 \*Class of \*securities issued or to be issued

**Performance Rights** 

2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued

30 million performance rights issued under the Long-Term Incentive Plan (LTIP).

3 Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Performance rights issued in 3 equal tranches of 10 million with both performance and share price vesting conditions over three years: -

- 1. Tranche 1 vesting on 30 day VWAP of \$0.004 or higher before December 31, 2019;
- Tranche 2 vesting on 30 day VWAP of \$0.006 or higher on or before December 31, 2020; and
- 3. Tranche 3 vesting on delivery of at least 1 million ounces resource at Chuscal before December 31, 2021.

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
	payment	
5	Issue price or consideration	Nil- Performance rights
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Award under the LTIP
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	None
6d	Number of *securities issued with security holder approval under rule 7.1A	None

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A	
6f	Number of *securities issued under an exception in rule 7.2	None	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	178,191,092	
7	*Issue dates  Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.	13 May 2019	
		Number	+01
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	1,187,940,614 547,345,422	*Class Ordinary Fully paid shares Options exercise price \$0.011 expiring 1 June 2020

<sup>+</sup> See chapter 19 for defined terms.

9. Number and \*class of all \*securities not quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	†Class	
12,345,639	Options exercisable at A\$0.08 per Option into Shares on or before 17 May 2019.	
12,345,639	Options exercisable at A\$0.08 per Option into Shares on or before 25 May 2019.	
46,400,000	Performance Rights (terms and conditions summarised in the notice of AGM announced 26 April 2018)	
9,600,000	LTIP Options exercisable at A\$0.016 each on or before 31 December 2019, subject to vesting conditions.	
9,600,000	LTIP Options exercisable at A\$0.024 each on or before 31 December 2020, subject to vesting conditions.	
306	Convertible Notes (CN) issued in single tranche but convertible into fully paid shares in two tranches:  1. Tranche 1 - 115 CN issued under existing	
	placement capacity LR 7.1 at a conversion price of \$0.003 per share.	
	2. Tranche 2 - 191 CN (issued as debt) and convertible subject to shareholder approval at \$0.003 per share.  (1.1.1.2.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1	
	If the Proposed Merger (ASX Announcement  13 March 19) does not proceed, the conversion price of the CN will be \$0.002 per	
	share.	
	Subject to shareholder approval there will be 1 free option per share exercisable at \$0.004 issued to the CN holders within 2 years from date of issue.	
30,000,000	Performance Rights exercisable in three equal tranches of 10 million:	
	<ol> <li>Tranche 1 vesting on 30 day VWAP of \$0.004 or higher before December 31, 2019;</li> <li>Tranche 2 vesting on 30 day VWAP of \$0.006</li> </ol>	
	or higher on or before December 31, 2020; and 3. Tranche 3 vesting on delivery of at least 1 million ounces resource at Chuscal before December 31, 2021.	
	or higher on or before December 31, 2020; and 3. Tranche 3 vesting on delivery of at least 1	

10	Dividen	d policy (in th	ne case of
	a trust,	distribution	policy) or
	the	increased	capita
	(interests)		

N/A			

## Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	

13	Ratio in which the <sup>+</sup> securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	
15	<sup>+</sup> Record date to determine entitlements	
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	
17	Policy for deciding entitlements in relation to fractions	
18	Names of countries in which the entity has security holders who will not be sent new offer documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	

<sup>+</sup> See chapter 19 for defined terms.

20	Names of any underwriters	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the issue	
23	Fee or commission payable to the broker to the issue	
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	their er	security holders dispose of ntitlements (except by sale a broker)?
33	<sup>+</sup> Issue da	ate
		uotation of securities applete this section if you are applying for quotation of securities
34	Type of (tick one	†securities e)
(a)	+	Securities described in Part 1
(b)	A	All other +securities
		Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee neentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entiti	ies that	have ticked box 34(a)
Additi	onal sec	urities forming a new class of securities
Tick to docume		you are providing the information or
35	L a	f the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders – see attachment
36	1 1 5 1	f the *securities are *equity securities, a distribution schedule of the additional securities setting out the number of holders in the categories – see attachment L - 1,000 L,001 - 5,000 5,001 - 10,000 L0,001 - 100,000 L00,001 and over
37		A copy of any trust deed for the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	<sup>+</sup> Class of <sup>+</sup> securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  the date from which they do  the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	<sup>+</sup> Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 

  †securities to be quoted under section 1019B of the Corporations Act at 
  the time that we request that the †securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Date: 14<sup>th</sup> May 2019

(Company secretary)

Wedne

Print name: Geoffrey Widmer

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid <sup>†</sup> ordinary securities on issue 12 months before the <sup>†</sup> issue date or date of agreement to issue	146,280,344	
<ul> <li>Number of fully paid *ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid *ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid *ordinary securities that became fully paid in that 12 month period</li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul> </li> <li>Subtract the number of fully paid *ordinary securities cancelled during that 12 month</li> </ul>	694,831,892 – Entitlement Offer (24/4/18) under Exception 1 of LR7.2  2,702,152 – Lanstead share issue (30/04/18) ratified AGM 28 May 2018 - LR 7.4  68,734,589 - Placement 22 May Placement ratified at EGM at 14 September - LR 7.4  88,867,687 shares - Entitlement offer (on or about 18/12/2018) - Exception 1 of LR 7.2  135,000,000 shares- placement 18 <sup>th</sup> October approved at 24 <sup>th</sup> December 2018 EGM-LR 7.4  23,950 shares from conversion of 23,950 Listed options with expiry date 01/06/2020 and an exercise price of \$0.011 per share  51,500,000 shares from Prospectus Placement Shortfall issued at \$0.003 per share (Rights Issue Prospectus closed 14 December 2018)	
period "A"	1,187.940,614	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15
	[Note: this value cannot be changed]
Multiply "A" by 0.15	178,191,092
Step 3: Calculate "C", the amount of pla already been used	cement capacity under rule 7.1 that has
<b>Insert</b> number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:	
Under an exception in rule 7.2	
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
<ul> <li>Note:         <ul> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> </ul> </li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	
"C"	
Step 4: Subtract "C" from ["A" x "B"] to under rule 7.1	calculate remaining placement capacity
"A" x 0.15	178,191,092
Note: number must be same as shown in Step 2	
Subtract "C"	0
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	178,191,092
	[Note: this is the remaining placement capacity under rule 7.1]

<sup>+</sup> See chapter 19 for defined terms.

### Part 2

The state of the s	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
Multiply "A" by 0.10		
Step 3: Calculate "E", the amount of placalready been used	cement capacity under rule 7.1A that ha	
	cement capacity under rule 7.1A that ha	

Appendix 3B Page 12 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

<sup>+</sup> See chapter 19 for defined terms.